CHOP Without Rituximab — Why R Is Sometimes Left Out

No. For lymphomas that do not express CD20, CHOP is the appropriate regimen — not a reduced one. Rituximab without a CD20 target would add infusion reactions and other side effects without contributing to treatment. The regimen you receive is chosen because it matches your tumour biology, not because something has been withheld.

CD20 status generally does not change during treatment, so the decision made at diagnosis usually stands for the whole course. In some situations — a revised diagnosis after more detailed pathology, or a reassessment — your oncologist may revisit the question. If you want to understand the reasoning, ask for the CD20 result in writing and ask what would change the decision.

The side effects of the four CHOP drugs still apply. These can include a fall in blood counts, increased risk of infection, hair loss, nausea, mouth sores, and nerve effects from vincristine such as tingling in the hands or feet. Without rituximab, you avoid the infusion reactions associated with the antibody — chills, fever and occasionally more serious reactions during the infusion itself. Your team will tell you which effects to watch for and when to call.

Yes, in some circumstances. A severe allergy or prior reaction to rituximab may mean it cannot safely be given. Certain other medical conditions may also affect the decision. These are individual clinical judgements made by your oncologist. If you have a CD20-positive lymphoma and rituximab is being omitted, ask your oncologist to explain the specific reason for your case.

A biosimilar is a version of rituximab produced by a different manufacturer after the original patent expired. To be approved, it must demonstrate equivalent clinical effect to the original product. Biosimilars have significantly reduced the cost of rituximab in India and are used widely. If cost is a concern for your family, ask your oncologist whether a biosimilar version is available and appropriate for your regimen.

Yes. The regimen should be named explicitly in your treatment plan before your first cycle begins. Ask your oncologist to confirm whether you are receiving CHOP or R-CHOP, what your CD20 result showed, and the reason for the choice. Writing the answers down helps — these conversations are hard to recall accurately afterwards, and the information is yours to keep and refer back to.